{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:27:10Z","timestamp":1786591630824,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10072-026-09295-8","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:58:12Z","timestamp":1785815892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database"],"prefix":"10.1007","volume":"47","author":[{"given":"Longtao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3577-1974","authenticated-orcid":false,"given":"Fangni","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"9295_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","volume":"391","author":"CM Tanner","year":"2024","unstructured":"Tanner CM, Ostrem JL (2024) Parkinson\u2019s Disease. N Engl J Med 391:442\u2013452. https:\/\/doi.org\/10.1056\/NEJMra2401857","journal-title":"N Engl J Med"},{"key":"9295_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12264-022-00934-6","volume":"39","author":"HN Costa","year":"2023","unstructured":"Costa HN, Esteves AR, Empadinhas N, Cardoso SM (2023) Parkinson\u2019s Disease: A Multisystem Disorder. Neurosci Bull 39:113\u2013124. https:\/\/doi.org\/10.1007\/s12264-022-00934-6","journal-title":"Neurosci Bull"},{"key":"9295_CR3","doi-asserted-by":"publisher","first-page":"112610","DOI":"10.1016\/j.biopha.2021.112610","volume":"146","author":"MT Kabir","year":"2022","unstructured":"Kabir MT, Rahman MH, Shah M et al (2022) Therapeutic promise of carotenoids as antioxidants and anti-inflammatory agents in neurodegenerative disorders. Biomed Pharmacother 146:112610","journal-title":"Biomed Pharmacother"},{"key":"9295_CR4","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C et al (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"key":"9295_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/wco.0000000000001166","volume":"36","author":"R Wang","year":"2023","unstructured":"Wang R, Shih LC (2023) Parkinson\u2019s disease - current treatment. Curr Opin Neurol 36:302\u2013308. https:\/\/doi.org\/10.1097\/wco.0000000000001166","journal-title":"Curr Opin Neurol"},{"key":"9295_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T et al (2025) Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm (Vienna) 132:743\u2013779. https:\/\/doi.org\/10.1007\/s00702-025-02893-4","journal-title":"J Neural Transm (Vienna)"},{"key":"9295_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/08971900221151194","volume":"37","author":"C Livingston","year":"2024","unstructured":"Livingston C, Monroe-Duprey L (2024) A Review of Levodopa Formulations for the Treatment of Parkinson\u2019s Disease Available in the United States. J Pharm Pract 37:485\u2013494. https:\/\/doi.org\/10.1177\/08971900221151194","journal-title":"J Pharm Pract"},{"key":"9295_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00702-024-02828-5","volume":"131","author":"T M\u00fcller","year":"2024","unstructured":"M\u00fcller T, Gerlach M, Hefner G, Hiemke C, Jost WH, Riederer P (2024) Therapeutic drug monitoring in Parkinson\u2019s disease. J Neural Transm (Vienna) 131:1247\u20131262. https:\/\/doi.org\/10.1007\/s00702-024-02828-5","journal-title":"J Neural Transm (Vienna)"},{"key":"9295_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00702-024-02825-8","volume":"131","author":"WH Jost","year":"2024","unstructured":"Jost WH (2024) Dopamine agonists in the treatment of Parkinson\u2019s disease: the show must go on. J Neural Transm (Vienna) 131:1471\u20131480. https:\/\/doi.org\/10.1007\/s00702-024-02825-8","journal-title":"J Neural Transm (Vienna)"},{"key":"9295_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.62641\/aep.v52i6.1711","volume":"52","author":"Q Liu","year":"2024","unstructured":"Liu Q, Wang H, Lv S et al (2024) The Combined Use of Levodopa\/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson\u2019s Disease. Actas Esp Psiquiatr 52:769\u2013776. https:\/\/doi.org\/10.62641\/aep.v52i6.1711","journal-title":"Actas Esp Psiquiatr"},{"key":"9295_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17425255.2023.2249404","volume":"19","author":"P Ayuso","year":"2023","unstructured":"Ayuso P, Jim\u00e9nez-Jim\u00e9nez FJ, G\u00f3mez-Tabales J, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Ag\u00fandez JAG (2023) An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 19:447\u2013460. https:\/\/doi.org\/10.1080\/17425255.2023.2249404","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"9295_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40264-025-01560-7","volume":"48","author":"S Janiczak","year":"2025","unstructured":"Janiczak S, Tanveer S, Tom K et al (2025) An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System. Drug Saf 48:1119\u20131126. https:\/\/doi.org\/10.1007\/s40264-025-01560-7","journal-title":"Drug Saf"},{"key":"9295_CR13","doi-asserted-by":"publisher","unstructured":"Magalh\u00e3es T, Dinis-Oliveira RJ, Taveira-Gomes T (2022) Digital health and big data analytics: implications of real-world evidence for clinicians and policymakers. Int J Environ Res Public Health 19. https:\/\/doi.org\/10.3390\/ijerph19148364","DOI":"10.3390\/ijerph19148364"},{"key":"9295_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG (2004) Using MedDRA: implications for risk management. Drug Saf 27:591\u2013602. https:\/\/doi.org\/10.2165\/00002018-200427080-00010","journal-title":"Drug Saf"},{"key":"9295_CR15","doi-asserted-by":"publisher","first-page":"e16535","DOI":"10.1111\/ene.16535","volume":"32","author":"D Santos-Garc\u00eda","year":"2025","unstructured":"Santos-Garc\u00eda D, L\u00f3pez\u2010Manzanares L, Muro I et al (2025) Effectiveness and safety of levodopa\u2013entacapone\u2013carbidopa infusion in Parkinson disease: A real\u2010world data study. Eur J Neurol 32:e16535","journal-title":"Eur J Neurol"},{"key":"9295_CR16","doi-asserted-by":"crossref","unstructured":"Sepp\u00e4nen P, Forsberg MM, Tiihonen M, Laitinen H, Beal S, Dorman DC (2024) A systematic review and meta-analysis of the efficacy and safety of rasagiline or pramipexole in the treatment of early parkinson\u2019s disease. Parkinson\u2019s Disease 2024:8448584","DOI":"10.1155\/2024\/8448584"},{"key":"9295_CR17","first-page":"491","volume":"102","author":"Y Wan","year":"2022","unstructured":"Wan Y, Xiao R, Zhao J et al (2022) The clinical efficacy of the stratification medical treatment based on the risk estimation of motor complications in Parkinson\u2019s disease. Zhonghua yi xue za zhi 102:491\u2013498","journal-title":"Zhonghua yi xue za zhi"},{"key":"9295_CR18","doi-asserted-by":"publisher","first-page":"e20180148","DOI":"10.1590\/1806-3713\/e20180148","volume":"45","author":"AS Santos RBd, Fraga","year":"2019","unstructured":"Santos RBd, Fraga AS, Coriolano, MdGWdS et al (2019) Respiratory muscle strength and lung function in the stages of Parkinson\u2019s disease. Jornal Brasileiro de Pneumologia 45:e20180148","journal-title":"Jornal Brasileiro de Pneumologia"},{"key":"9295_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00702-018-1890-4","volume":"125","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Murgia N, Nigro P et al (2018) Levodopa-responsive breathing discomfort in Parkinson\u2019s disease patients. J Neural Transm 125:1033\u20131036","journal-title":"J Neural Transm"},{"key":"9295_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000536310","volume":"102","author":"ML Lim","year":"2024","unstructured":"Lim ML, Zhan AB, Liu SJ et al (2024) Awake versus asleep anesthesia in deep brain stimulation surgery for Parkinson\u2019s disease: a systematic review and meta-analysis. Stereotact Funct Neurosurg 102:141\u2013155","journal-title":"Stereotact Funct Neurosurg"},{"key":"9295_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Hauser RA, Grosset DG et al (2016) A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord 31:1356\u20131365","journal-title":"Mov Disord"},{"key":"9295_CR22","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3233\/JPD-213121","volume":"12","author":"VA van de Wetering-van Dongen","year":"2022","unstructured":"van de Wetering-van Dongen VA, Nijkrake MJ, Koenders N, van der Wees PJ, Bloem BR, Kalf JG (2022) Experienced respiratory symptoms and the impact on daily life from the perspective of people with Parkinson\u2019s disease: a grounded theory. J Parkinson\u2019s Disease 12:1677\u20131691","journal-title":"J Parkinson\u2019s Disease"},{"key":"9295_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/life13041043","volume":"13","author":"A Tundo","year":"2023","unstructured":"Tundo A, Betro\u2019 S, de Filippis R et al (2023) Pramipexole augmentation for treatment-resistant unipolar and bipolar depression in the real world: a systematic review and meta-analysis. Life 13:1043","journal-title":"Life"},{"key":"9295_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P (2015) Parkinson\u2019s disease treatment may cause impulse\u2013control disorder via dopamine D3 receptors. Synapse 69:183\u2013189","journal-title":"Synapse"},{"key":"9295_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.01.113","volume":"58","author":"LE De Wit","year":"2022","unstructured":"De Wit LE, Wilting I, Souverein PC, van der Pol P, Egberts TC (2022) Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase. Eur Neuropsychopharmacol 58:30\u201338","journal-title":"Eur Neuropsychopharmacol"},{"key":"9295_CR26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Castrillo JCM, Alonso-Canovas A et al (2014) Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840\u2013844","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9295_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.irn.2025.02.005","volume":"181","author":"P Cumming","year":"2025","unstructured":"Cumming P, Egger K, Knudsen GM (2025) Molecular brain imaging of psychedelic action. Int Rev Neurobiol 181:203\u2013230","journal-title":"Int Rev Neurobiol"},{"key":"9295_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mds.27898","volume":"35","author":"E Martinez","year":"2020","unstructured":"Martinez E, Pasquereau B, Saga Y, M\u00e9t\u00e9reau \u00c9, Tremblay L (2020) The anterior caudate nucleus supports impulsive choices triggered by pramipexole. Mov Disord 35:296\u2013305","journal-title":"Mov Disord"},{"key":"9295_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10072-023-07006-1","volume":"45","author":"A Gunduz","year":"2024","unstructured":"Gunduz A, \u00c7ift\u00e7i T, Erbil AC, Senoglu G, Ser MH, Apayd\u0131n H (2024) Impulse control disorders in Parkinson\u2019s disease: a retrospective analysis of 1824 patients in a 12-year period. Neurol Sci 45:171\u2013175","journal-title":"Neurol Sci"},{"key":"9295_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595","journal-title":"Arch Neurol"},{"key":"9295_CR31","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","volume":"95","author":"C Chen","year":"2021","unstructured":"Chen C, Wu B, Zhang C, Xu T (2021) Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol 95:107498","journal-title":"Int Immunopharmacol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09295-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:41:25Z","timestamp":1786588885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9295"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09295-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"679"}}